Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulators

Journal of Medicinal Chemistry

Volumn 57, Issue 3, 2014, Pages 1046-1062

  Pettersson, Martin ^a   Johnson, Douglas S ^a   Subramanyam, Chakrapani ^a   Bales, Kelly R ^a   Am Ende, Christopher W ^a   Fish, Benjamin A ^a   Green, Michael E ^a   Kauffman, Gregory W ^a   Mullins, Patrick B ^a   Navaratnam, Thayalan ^a   Sakya, Subas M ^a   Stiff, Cory M ^a   Tran, Tuan P ^a   Xie, Longfei ^a   Zhang, Liming ^a   Pustilnik, Leslie R ^a   Vetelino, Beth C ^a   Wood, Kathleen M ^a   Pozdnyakov, Nikolay ^a   Verhoest, Patrick R ^a   O'Donnell, Christopher J ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BINDING SITES; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; GUINEA PIGS; HEK293 CELLS; HUMANS; PEPTIDE FRAGMENTS; PRESENILIN-1; PYRIDAZINES; PYRIDINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84894090394     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401782h     Document Type: Article

References (62)

1. Thies, W.; Bleiler, L. 2013 Alzheimer's disease facts and figures. Alzheimer's Dementia 2013, 9, 208-245.
2. Bertram, L.; Tanzi, R. E. The genetics of Alzheimer's disease Prog. Mol. Biol. Transl. Sci. 2012, 107, 79-100
3. Walsh, D. M.; Selkoe, D. J. Aβ oligomers-a decade of discovery J. Neurochem. 2007, 101, 1172-1184
4. Karran, E.; Mercken, M.; De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics Nat. Rev. Drug Discovery 2011, 10, 698-712
5. De Strooper, B.; Vassar, R.; Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer disease Nat. Rev. Neurol. 2010, 6, 99-107
6. Bateman, R. J.; Siemers, E. R.; Mawuenyega, K. G.; Wen, G.; Browning, K. R.; Sigurdson, W. C.; Yarasheski, K. E.; Friedrich, S. W.; DeMattos, R. B.; May, P. C.; Paul, S. M.; Holtzman, D. M. A γ-secretase inhibitor decreases amyloid-β production in the central nervous system Ann. Neurol. 2009, 66, 48-54
7. Tong, G.; Castaneda, L.; Wang, J.-S.; Sverdlov, O.; Huang, S.-P.; Slemmon, R.; Gu, H.; Wong, O.; Li, H.; Berman, R. M.; Smith, C.; Albright, C.; Dockens, R. C. Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men Clin. Drug Invest. 2012, 32, 761-769
8. Imbimbo, B. P.; Panza, F.; Frisardi, V.; Solfrizzi, V.; D'Onofrio, G.; Logroscino, G.; Seripa, D.; Pilotto, A. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: Still a viable option? Expert Opin. Invest. Drugs 2011, 20, 325-341
9. Sambamurti, K.; Greig, N. H.; Utsuki, T.; Barnwell, E. L.; Sharma, E.; Mazell, C.; Bhat, N. R.; Kindy, M. S.; Lahiri, D. K.; Pappolla, M. A. Targets for AD treatment: conflicting messages from γ-secretase inhibitors J. Neurochem. 2011, 117, 359-374
10. Schor, N. F. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us Ann. Neurol. 2011, 69, 237-239
11. Coric, V.; van Dyck, C. H.; Salloway, S.; Andreasen, N.; Brody, M.; Richter, R. W.; Soininen, H.; Thein, S.; Shiovitz, T.; Pilcher, G.; Colby, S.; Rollin, L.; Dockens, R.; Pachai, C.; Portelius, E.; Andreasson, U.; Blennow, K.; Soares, H.; Albright, C.; Feldman, H. H.; Berman, R. M. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease Arch. Neurol. 2012, 69, 1430-1440
12. Haapasalo, A.; Kovacs, D. M. The many substrates of presenilin/γ- secretase J. Alzheimer's Dis. 2011, 25, 3-28
13. Mitani, Y.; Yarimizu, J.; Saita, K.; Uchino, H.; Akashiba, H.; Shitaka, Y.; Ni, K.; Matsuoka, N. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice J. Neurosci. 2012, 32, 2037-2050
14. Weggen, S.; Eriksen, J. L.; Das, P.; Sagi, S. A.; Wang, R.; Pietrzik, C. U.; Findlay, K. A.; Smith, T. E.; Murphy, M. P.; Bulter, T.; Kang, D. E.; Marquez-Sterling, N.; Golde, T. E.; Koo, E. H. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity Nature 2001, 414, 212-216
15. Eriksen, J. L.; Sagi, S. A.; Smith, T. E.; Weggen, S.; Das, P.; McLendon, D. C.; Ozols, V. V.; Jessing, K. W.; Zavitz, K. H.; Koo, E. H.; Golde, T. E. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo J. Clin. Invest. 2003, 112, 440-449
16. Weggen, S.; Eriksen, J. L.; Sagi, S. A.; Pietrzik, C. U.; Golde, T. E.; Koo, E. H. Aβ42-Lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain J. Biol. Chem. 2003, 278, 30748-30754
17. Weggen, S.; Eriksen, J. L.; Sagi, S. A.; Pietrzik, C. U.; Ozols, V.; Fauq, A.; Golde, T. E.; Koo, E. H. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β42 production by direct modulation of γ-secretase activity J. Biol. Chem. 2003, 278, 31831-31837
18. Pettersson, M.; Stepan, A. F.; Kauffman, G. W.; Johnson, D. S. Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012 Expert Opin. Ther. Pat. 2013, 23, 1349-1366
19. Pettersson, M.; Kauffman, G. W.; am Ende, C. W.; Patel, N. C.; Stiff, C.; Tran, T. P.; Johnson, D. S. Novel γ-secretase modulators: a review of patents from 2008 to 2010 Expert Opin. Ther. Pat. 2011, 21, 205-226
20. Oehlrich, D.; Berthelot, D. J.-C.; Gijsen, H. J. M. γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs J. Med. Chem. 2011, 54, 669-698
21. Green, R. C.; Schneider, L. S.; Amato, D. A.; Beelen, A. P.; Wilcock, G.; Swabb, E. A.; Zavitz, K. H. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial JAMA, J. Am. Med. Assoc. 2009, 302, 2557-2564
22. Page, R. M.; Baumann, K.; Tomioka, M.; Pérez-Revuelta, B. I.; Fukumori, A.; Jacobsen, H.; Flohr, A.; Luebbers, T.; Ozmen, L.; Steiner, H.; Haass, C. Generation of Aβ38 and Aβ42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and γ-secretase modulation J. Biol. Chem. 2008, 283, 677-683
23. Ohki, Y.; Higo, T.; Uemura, K.; Shimada, N.; Osawa, S.; Berezovska, O.; Yokoshima, S.; Fukuyama, T.; Tomita, T.; Iwatsubo, T. Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1 EMBO J. 2011, 30, 4815-4824
24. Crump, C. J.; Fish, B. A.; Castro, S. V.; Chau, D.-M.; Gertsik, N.; Ahn, K.; Stiff, C.; Pozdnyakov, N.; Bales, K. R.; Johnson, D. S.; Li, Y.-M. Piperidine acetic acid based γ-secretase modulators directly bind to presenilin-1 ACS Chem. Neurosci. 2011, 2, 705-710
25. Hashimoto, T.; Ishibashi, A.; Hagiwara, H.; Murata, Y.; Takenaka, O.; Miyagawa, T. E2012: A novel gamma-secretase modulator-pharmacology Alzheimer's Dementia 2010, 6 (Suppl) S242
26. Portelius, E.; Van Broeck, B.; Andreasson, U.; Gustavsson, M. K.; Mercken, M.; Zetterberg, H.; Borghys, H.; Blennow, K. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs J. Alzheimer's Dis. 2010, 21, 1005-1012
27. De Strooper, B.; Iwatsubo, T.; Wolfe, M. S. Presenilins and γ-secretase: structure, function, and role in Alzheimer disease Cold Spring Harbor Perspect. Med. 2012, 2, a006304
28. Crump, C. J.; Johnson, D. S.; Li, Y.-M. Development and mechanism of γ-secretase modulators for Alzheimer's disease Biochemistry 2013, 52, 3197-3216
29. Pozdnyakov, N.; Murrey, H. E.; Crump, C. J.; Pettersson, M.; Ballard, T. E.; am Ende, C. W.; Ahn, K.; Li, Y.-M.; Bales, K. R.; Johnson, D. S. γ-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin J. Biol. Chem. 2013, 288, 9710-9720
30. Crump, C. J.; am Ende, C. W.; Ballard, T. E.; Pozdnyakov, N.; Pettersson, M.; Chau, D.-M.; Bales, K. R.; Li, Y.-M.; Johnson, D. S. Development of clickable active site-directed photoaffinity probes for γ-secretase Bioorg. Med. Chem. Lett. 2012, 22, 2997-3000
31. Crump, C. J.; Johnson, D. S.; Li, Y.-M. Target of γ-secretase modulators, presenilin marks the spot EMBO J. 2011, 30, 4696-4698
32. Ebke, A.; Luebbers, T.; Fukumori, A.; Shirotani, K.; Haass, C.; Baumann, K.; Steiner, H. Novel γ-secretase enzyme modulators directly target presenilin protein J. Biol. Chem. 2011, 286, 37181-37186
33. Jumpertz, T.; Rennhack, A.; Ness, J.; Baches, S.; Pietrzik, C. U.; Bulic, B.; Weggen, S. Presenilin is the molecular target of acidic γ-secretase modulators in living cells PLoS ONE 2012, 7, e30484
34. Pettersson, M.; Johnson, D. S.; Subramanyam, C.; Bales, K. R.; am Ende, C. W.; Fish, B. A.; Green, M. E.; Kauffman, G. W.; Lira, R.; Mullins, P. B.; Navaratnam, T.; Sakya, S. M.; Stiff, C. M.; Tran, T. P.; Vetelino, B. C.; Xie, L.; Zhang, L.; Pustilnik, L. R.; Wood, K. M.; O'Donnell, C. J. Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators Bioorg. Med. Chem. Lett. 2012, 22, 2906-2911
35. Oehlrich, D.; Rombouts, F. J.; Berthelot, D.; Bischoff, F. P.; De Cleyn, M. A.; Jaroskova, L.; Macdonald, G.; Mercken, M.; Surkyn, M.; Trabanco, A. A.; Tresadern, G.; Van Brandt, S.; Velter, A. I.; Wu, T.; Gijsen, H. J. Design and synthesis of bicyclic heterocycles as potent gamma-secretase modulators Bioorg. Med. Chem. Lett. 2013, 23, 4794-4800
36. Chen, J. J.; Qian, W.; Biswas, K.; Yuan, C.; Amegadzie, A.; Liu, Q.; Nixey, T.; Zhu, J.; Ncube, M.; Rzasa, R. M.; Chavez, F., Jr.; Chen, N.; Demorin, F.; Rumfelt, S.; Tegley, C. M.; Allen, J. R.; Hitchcock, S.; Hungate, R.; Bartberger, M. D.; Zalameda, L.; Liu, Y.; McCarter, J. D.; Zhang, J.; Zhu, L.; Babu-Khan, S.; Luo, Y.; Bradley, J.; Wen, P. H.; Reid, D. L.; Koegler, F.; Dean, C., Jr.; Hickman, D.; Correll, T. L.; Williamson, T.; Wood, S. Discovery of 2-methylpyridine-based biaryl amides as gamma-secretase modulators for the treatment of Alzheimer's disease Bioorg. Med. Chem. Lett. 2013, 23, 6447-6454
37. Bischoff, F.; Berthelot, D.; De Cleyn, M.; Macdonald, G.; Minne, G.; Oehlrich, D.; Pieters, S.; Surkyn, M.; Trabanco, A. A.; Tresadern, G.; Van Brandt, S.; Velter, I.; Zaja, M.; Borghys, H.; Masungi, C.; Mercken, M.; Gijsen, H. J. Design and synthesis of a novel series of bicyclic heterocycles as potent gamma-secretase modulators J. Med. Chem. 2012, 55, 9089-9106
38. Gijsen, H. J.; Mercken, M. γ-Secretase modulators: Can we combine potency with safety? Int. J. Alzheimer's Dis. 2012, 2012, 295207
39. Sun, Z. Y.; Asberom, T.; Bara, T.; Bennett, C.; Burnett, D.; Chu, I.; Clader, J.; Cohen-Williams, M.; Cole, D.; Czarniecki, M.; Durkin, J.; Gallo, G.; Greenlee, W.; Josien, H.; Huang, X.; Hyde, L.; Jones, N.; Kazakevich, I.; Li, H.; Liu, X.; Lee, J.; Maccoss, M.; Mandal, M. B.; McCracken, T.; Nomeir, A.; Mazzola, R.; Palani, A.; Parker, E. M.; Pissarnitski, D. A.; Qin, J.; Song, L.; Terracina, G.; Vicarel, M.; Voigt, J.; Xu, R.; Zhang, L.; Zhang, Q.; Zhao, Z.; Zhu, X.; Zhu, Z. Cyclic hydroxyamidines as amide isosteres: Discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ-secretase modulators in vivo J. Med. Chem. 2012, 55, 489-502. Also see ref 37. For comprehensive reviews, see ref 11
40. Values for clogP were calculated using the BIOBYTE (www.biobyte.com) program clogP, version 4.3.
41. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
42. Ryckmans, T.; Edwards, M. P.; Horne, V. A.; Correia, A. M.; Owen, D. R.; Thompson, L. R.; Tran, I.; Tutt, M. F.; Young, T. Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A lipophilic efficiency (LipE) analysis Bioorg. Med. Chem. Lett. 2009, 19, 4406-4409
43. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435-449
44. Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; DeCrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 2008, 18, 4872-4875
45. Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes ACS Chem. Neurosci. 2010, 1, 420-434
46. Chrzanowska, M.; Rozwadowska, M. D. Asymmetric synthesis of isoquinoline alkaloids Chem. Rev. 2004, 104, 3341-3370
47. Hendrickson, J. B.; Rodríguez, C. An efficient synthesis of substituted isoquinolines J. Org. Chem. 1983, 48, 3344-3346
48. Stepan, A. F.; Karki, K.; McDonald, W. S.; Dorff, P. H.; Dutra, J. K.; Dirico, K. J.; Won, A.; Subramanyam, C.; Efremov, I. V.; O'Donnell, C. J.; Nolan, C. E.; Becker, S. L.; Pustilnik, L. R.; Sneed, B.; Sun, H.; Lu, Y.; Robshaw, A. E.; Riddell, D.; O'Sullivan, T. J.; Sibley, E.; Capetta, S.; Atchison, K.; Hallgren, A. J.; Miller, E.; Wood, A.; Obach, R. S. Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors J. Med. Chem. 2011, 54, 7772-7783
49. Riley, R. J.; McGinnity, D. F.; Austin, R. P. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes Drug Metab. Dispos. 2005, 33, 1304-1311
50. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes Drug Metab. Dispos. 1999, 27, 1350-1359
51. Feng, B.; Mills, J. B.; Davidson, R. E.; Mireles, R. J.; Janiszewski, J. S.; Troutman, M. D.; de Morais, S. M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system Drug Metab. Dispos. 2008, 36, 268-275
52. A compound with a MDR efflux ratio (MDR Er) less than 2.5 is considered to have minimal P-gp efflux liability.
53. Callegari, E.; Malhotra, B.; Bungay, P. J.; Webster, R.; Fenner, K. S.; Kempshall, S.; LaPerle, J. L.; Michel, M. C.; Kay, G. G. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder Br. J. Clin. Pharmacol. 2011, 72, 235-246
54. Parkinson, A.; Ogilvie, B. W. Biotransformation of Xenobiotics. In Casarett & Doull's Toxicology, The Basic Science of Poisons, 7 th ed.; Klaassen, C. D., Ed.; The McGraw-Hill Co., Inc.: New York, 2008; Chapter 6, pp 161-304. Also available online: http://ilmufarmasis.files.wordpress.com/2011/07/ casarett- and-doulls-toxicology-the-basic-science-of-poisons7th-ed.pdf (accessed Oct 23, 2013).
55. Wai, J. S.; Kim, B.; Fisher, T. E.; Zhuang, L.; Embrey, M. W.; Williams, P. D.; Staas, D. D.; Culberson, C.; Lyle, T. A.; Vacca, J. P.; Hazuda, D. J.; Felock, P. J.; Schleif, W. A.; Gabryelski, L. J.; Jin, L.; Chen, I.-W.; Ellis, J. D.; Mallai, R.; Young, S. D. Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 5595-5599
56. Kawahara, N.; Nakajima, T.; Itoh, T.; Ogura, H. A Synthesis of pyrido[1,2- a ]quinoxalines and pyrido[1,2- a ]pyrazines Heterocycles 1983, 20, 1721-1725
57. Tran, T. P.; Mullins, P. B.; am Ende, C. W.; Pettersson, M. Synthesis of pyridopyrazine-1,6-diones from 6-hydroxypicolinic acids via a one-pot coupling/cyclization reaction Org. Lett. 2013, 15, 642-645
58. am Ende, C. W.; Johnson, D. S.; O'Donnell, C. J.; Pettersson, M. Y.; Subramanyam, C. Preparation of heteroaryl imidazoles and heteroaryl triazoles as γ-secretase modulators. WO2011048525A1, 2011.
59. Assay method adapted from published protocol: Hay, T.; Jones, R.; Beaumont, K.; Kemp, M. Modulation of the partition coefficient between octanol and buffer at pH 7.4 and pKa to achieve the optimum balance of blood clearance and volume of distribution for a series of tetrahydropyran histamine type 3 receptor antagonists Drug Metab. Dispos. 2009, 37, 1864-1870
60. Solubility was measured by Analiza, Inc., Cleveland, OH. (http://analiza.com/physchem/logd.html#qf.
61. Borgegard, T.; Jureus, A.; Olsson, F.; Rosqvist, S.; Sabirsh, A.; Rotticci, D.; Paulsen, K.; Klintenberg, R.; Yan, H.; Waldman, M.; Stromberg, K.; Nord, J.; Johansson, J.; Regner, A.; Parpal, S.; Malinowsky, D.; Radesater, A. C.; Li, T.; Singh, R.; Eriksson, H.; Lundkvist, J. First and second generation gamma-secretase modulators (gsms) modulate amyloid-beta (abeta) peptide production through different mechanisms J. Biol. Chem. 2012, 287, 11810-11819
62. Lapinsky, D. J. Tandem photoaffinity labeling-bioorthogonal conjugation in medicinal chemistry Bioorg. Med. Chem. 2012, 20, 6237-6247